Trial Profile
A TWO-COHORT, OPEN-LABEL, MULTICENTER, STUDY OF TRASTUZUMAB EMTANSINE (T-DM1) IN HER2-POSITIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PATIENTS WHO HAVE RECEIVED PRIOR ANTI-HER2 AND CHEMOTHERAPY-BASED TREATMENT
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Advanced breast cancer; Brain metastases; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions; Registrational
- Acronyms KAMILLA
- Sponsors Roche
- 08 Jun 2021 Final results from KAMILLA Cohorts 1 (global) and 2 (Asia) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 09 Sep 2020 Status changed from active, no longer recruiting to completed.
- 04 Jul 2020 Results (n=2003) of exploratory final analysis of cohort 1 from KAMILLA published in the Annals of Oncology